BenevolentAI, AstraZeneca AI-based drug discovery collaboration achieves third milestone

BenevolentAI has discovered a second novel target for idiopathic pulmonary fibrosis (IPF), which AstraZeneca has added to its drug development portfolio, resulting in a milestone payment to the London-based research firm.